Since targeting PP2A can enhance ICB response through modification of both tumours-intrinsic and extrinsic factors, the in vivo anti-cancer immunotherapy effect of systemic administration of LB-100 should be better than that of Ppp2r1a gene knockdown in mouse cancer cells. Here, PPP2R1A is linked to neoplasm.